Skip to main content

Table 2 Adverse events of CPT-11/NDP chemotherapy

From: UGT1A1 polymorphism has a prognostic effect in patients with stage IB or II uterine cervical cancer and one or no metastatic pelvic nodes receiving irinotecan chemotherapy: a retrospective study

UGT1A1 Wild-type (24 cases) Polymorphism (hetero/homo, n = 23/4 cases) P-value
Neutropenia 7 15 0.09
Grade 3 5 12 0.13
Grade 4 2 3 > 0.99
Febrile neutropenia 1 1 >  0.99
Nausea (> Grade 3) 1 2 >  0.99
Diarrhea (> Grade 3) 4 3 0.69
Anorexia (> Grade 3) 0 2 0.49
Thrombocytopenia (> Grade 3) 0 1 >  0.99
  1. CPT-11/NDP Irinotecan/nedaplatin, UGT1A1 Uridine diphosphate glucuronosyltransferase 1 family polypeptide A1